Photo from wikipedia
Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with “advanced cirrhosis” because of its narrow therapeutic index. We aimed to better define the predicting… Click to show full abstract
Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with “advanced cirrhosis” because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non‐response in cirrhotic patients undergoing OCA therapy.
Keywords:
primary biliary;
biliary cholangitis;
serious adverse;
obeticholic acid;
patients primary;
adverse events
Journal Title: Liver International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Liver International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!